Does Vyvanse Help the Foggy Kind of ADHD?

I can start the task. I just cannot get my brain to come online.

That is the line I hear from a subset of adults with ADHD. This is not the restless picture. Foggy, slow to engage, staring, bored, spacey, even when they are trying. Fair. Standard ADHD language does not always capture that.

This piece was originally written with Isak Rabiyev, PMHNP. I updated it in August 2026 for newer research and terminology.

So, plainly: if someone has ADHD plus this disengaged, daydreamy pattern, lisdexamfetamine (Vyvanse) may improve some of those symptoms along with the usual ADHD ones. It has not been shown to be a specific treatment for a separate diagnosis. The cluster is not in the DSM. Researchers still argue whether it is its own condition or a pattern that rides with ADHD.

What people mean by this

Researchers used to call it sluggish cognitive tempo, or SCT. An international work group has since recommended cognitive disengagement syndrome, or CDS. The name change is not branding. Studies have not consistently shown that people with these symptoms literally process information more slowly. Daydreaming, mental fog, staring, reduced alertness, and trouble staying engaged with the room appear to be the more central features.

Barkley and others have asked for years whether this is a "second attention disorder." That question is still open. Fatigue, brain fog, and drifting also show up in depression, anxiety, sleep disorders, medical illness, substance use, and medication side effects. I would still be cautious about treating CDS as its own diagnosis in clinic.

The useful research question is narrower. If someone already has ADHD, and this fog is part of the picture, do standard ADHD medications help that part too?

What the Vyvanse study found

Adler and colleagues ran a small randomized, placebo-controlled crossover trial of lisdexamfetamine in adults with ADHD and prominent SCT symptoms (Journal of Clinical Psychiatry, 2021). Thirty-nine adults enrolled. Thirty-eight completed and were analyzed. Each person got Vyvanse for one four-week period and placebo for the other, with a washout in between. Dosing started at 30 mg a day and could go to 70 mg.

Vyvanse clearly improved standard ADHD symptoms: attention, executive functioning, overall impairment. That held across both treatment periods.

The SCT results were messier. Vyvanse produced a moderate to large improvement in daydreaming, mental fog, lethargy, and disengagement in both periods, but the difference from placebo only reached statistical significance in the first period. In the second period, SCT scores in both groups did not fully return to baseline after the washout. That possible carryover made the comparison harder to read.

Thirty-eight people is not enough to untangle that. It is early evidence, not a practice-changing trial. People with ADHD plus this foggier style may notice improvement on an amphetamine stimulant beyond the usual ADHD checklist. That is as far as I would take it.

What it can look like

For some people, treatment does more than help them sit still or finish a task.

Conversations are easier to follow. Reading takes less effort. They spend less time staring at a screen waiting for their brain to arrive. Tasks that felt mentally heavy get easier to start.

Adults with ADHD describe this very differently from one another. One person is restless and impulsive. Another drifts for hours, low mental energy, frequent daydreaming, trouble moving from thinking about a thing to doing it. Both can be ADHD. Sometimes both are the same person.

Side effects

In this study, side effects looked like Vyvanse elsewhere. Decreased appetite and headache were the most common. A smaller number reported anxiety. No serious adverse events. One person stopped because of a side effect.

That does not make Vyvanse a fit for everyone. Sleep, appetite, anxiety, heart history, substance use history, and what they have already tried all matter.

What has changed since

The terminology shifted. Becker and colleagues' 2023 work-group report is why you will see CDS more than SCT in newer papers.

The medication literature grew a little. A 2026 systematic review (Kılınçel et al., Frontiers in Psychiatry) found preliminary evidence that ADHD medications can improve CDS symptoms. The research base is still small. Atomoxetine and methylphenidate have been studied too. The Vyvanse evidence still leans on that original adult trial.

So the original finding still holds up reasonably well, with a qualification. Vyvanse may improve cognitive disengagement symptoms in people who also have ADHD. It has not been established as a specific treatment for CDS.

If you have ADHD and this fog is part of what you live with, treating the ADHD may help some of the fog too. The research is encouraging and small. I would still look hard at sleep, mood, medical causes, and substances before parking the whole picture on CDS.

Which medication, if any, is a conversation with a clinician who knows your history.

This is general information, not personalized medical advice. Don't start, stop, or change a medication without talking to your own clinician.

References

Adler LA, Leon TL, Sardoff TM, et al. A placebo-controlled trial of lisdexamfetamine in the treatment of comorbid sluggish cognitive tempo and adult ADHD. Journal of Clinical Psychiatry. 2021;82(4):20m13687.

Saxbe C, Barkley RA. The second attention disorder? Sluggish cognitive tempo vs. attention-deficit/hyperactivity disorder: Update for clinicians. Journal of Psychiatric Practice. 2014;20(1):38–49.

Becker SP, Willcutt EG, Leopold DR, et al. Report of a Work Group on Sluggish Cognitive Tempo: Key research directions and a consensus change in terminology to cognitive disengagement syndrome. Journal of the American Academy of Child & Adolescent Psychiatry. 2023;62(6):629–645.

Kılınçel Ş, Bulut F, Göksel P, et al. Preliminary efficacy of pharmacological treatments on sluggish cognitive tempo (cognitive disengagement syndrome): A systematic review and meta-analysis. Frontiers in Psychiatry. 2026.